Sebia

Sebia is a global, specialized player in the in vitro diagnostics market, with a 50+ year history. The company's core expertise lies in protein separation and detection technologies, primarily capillary and gel electrophoresis, complemented by ELISA, IFA, and its proprietary SMC Technology. With over 20,000 instruments installed worldwide and a presence in more than 120 countries, Sebia has established a strong commercial footprint. Its business model is focused on providing integrated systems (instruments, consumables, software, and services) for clinical laboratories, generating recurring revenue from test kits and service contracts.

Integrated diagnostics platforms centered on Capillary Electrophoresis, Gel Electrophoresis, Immunofixation (IFA), ELISA, and proprietary SMC Technology for automated, barcode-driven calibration and quality control on the Alegria 2 system.

Sebia competes in the specialized protein diagnostics segment against large, diversified IVD companies like Siemens Healthineers, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer broader portfolios. It also faces competition from other focused electrophoresis and immunoassay companies. Its differentiation lies in its deep specialization, integrated systems, and proprietary technologies like SMC.